| Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells P André, C Denis, C Soulas, C Bourbon-Caillet, J Lopez, T Arnoux, ... Cell 175 (7), 1731-1743. e13, 2018 | 1107 | 2018 |
| Harnessing innate immunity in cancer therapy O Demaria, S Cornen, M Daëron, Y Morel, R Medzhitov, E Vivier Nature 574 (7776), 45-56, 2019 | 793 | 2019 |
| Identification, activation, and selective in vivo ablation of mouse NK cells via NKp46 T Walzer, M Bléry, J Chaix, N Fuseri, L Chasson, SH Robbins, S Jaeger, ... Proceedings of the National Academy of Sciences 104 (9), 3384-3389, 2007 | 600 | 2007 |
| Association of COVID-19 inflammation with activation of the C5a–C5aR1 axis J Carvelli, O Demaria, F Vély, L Batista, N Chouaki Benmansour, J Fares, ... Nature 588 (7836), 146-150, 2020 | 512 | 2020 |
| Multifunctional natural killer cell engagers targeting NKp46 trigger protective tumor immunity L Gauthier, A Morel, N Anceriz, B Rossi, A Blanchard-Alvarez, G Grondin, ... Cell 177 (7), 1701-1713. e16, 2019 | 404 | 2019 |
| Blocking antibodies targeting the CD39/CD73 immunosuppressive pathway unleash immune responses in combination cancer therapies I Perrot, HA Michaud, M Giraudon-Paoli, S Augier, A Docquier, L Gros, ... Cell reports 27 (8), 2411-2425. e9, 2019 | 398 | 2019 |
| Nucleic acid agonists for Toll‐like receptor 7 are defined by the presence of uridine ribonucleotides SS Diebold, C Massacrier, S Akira, C Paturel, Y Morel, C Reis e Sousa European journal of immunology 36 (12), 3256-3267, 2006 | 353 | 2006 |
| Phosphostim-activated γδ T cells kill autologous metastatic renal cell carcinoma E Viey, G Fromont, B Escudier, Y Morel, S Da Rocha, S Chouaib, ... The Journal of Immunology 174 (3), 1338-1347, 2005 | 275 | 2005 |
| Reciprocal expression of the TNF family receptor herpes virus entry mediator and its ligand LIGHT on activated T cells: LIGHT down-regulates its own receptor Y Morel, JM Schiano de Colella, J Harrop, KC Deen, SD Holmes, ... The Journal of Immunology 165 (8), 4397-4404, 2000 | 239 | 2000 |
| The TNF superfamily members LIGHT and CD154 (CD40 ligand) costimulate induction of dendritic cell maturation and elicit specific CTL activity Y Morel, A Truneh, RW Sweet, D Olive, RT Costello The Journal of Immunology 167 (5), 2479-2486, 2001 | 230 | 2001 |
| TLR3 as a biomarker for the therapeutic efficacy of double-stranded RNA in breast cancer B Salaun, L Zitvogel, C Asselin-Paturel, Y Morel, K Chemin, C Dubois, ... Cancer research 71 (5), 1607-1614, 2011 | 145 | 2011 |
| Plasmacytoid dendritic cell–derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists D Rajagopal, C Paturel, Y Morel, S Uematsu, S Akira, SS Diebold Blood, The Journal of the American Society of Hematology 115 (10), 1949-1957, 2010 | 136 | 2010 |
| TLR3 and Rig-like receptor on myeloid dendritic cells and Rig-like receptor on human NK cells are both mandatory for production of IFN-γ in response to double-stranded RNA I Perrot, F Deauvieau, C Massacrier, N Hughes, P Garrone, I Durand, ... The Journal of Immunology 185 (4), 2080-2088, 2010 | 127 | 2010 |
| Opposing effects of toll-like receptor (TLR3) signaling in tumors can be therapeutically uncoupled to optimize the anticancer efficacy of TLR3 ligands R Conforti, Y Ma, Y Morel, C Paturel, M Terme, S Viaud, B Ryffel, ... Cancer research 70 (2), 490-500, 2010 | 120 | 2010 |
| Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide IS Nijhof, JJL van Bueren, B van Kessel, P Andre, Y Morel, HM Lokhorst, ... Haematologica 100 (2), 263, 2015 | 115 | 2015 |
| Desirable cell death during anticancer chemotherapy C Locher, R Conforti, L Aymeric, Y Ma, T Yamazaki, S Rusakiewicz, ... Annals of the New York Academy of Sciences 1209 (1), 99-108, 2010 | 95 | 2010 |
| Identification of druggable inhibitory immune checkpoints on Natural Killer cells in COVID-19 O Demaria, J Carvelli, L Batista, ML Thibult, A Morel, P André, Y Morel, ... Cellular & molecular immunology 17 (9), 995-997, 2020 | 73 | 2020 |
| Control of acute myeloid leukemia by a trifunctional NKp46-CD16a-NK cell engager targeting CD123 L Gauthier, A Virone-Oddos, J Beninga, B Rossi, C Nicolazzi, C Amara, ... Nature Biotechnology 41 (9), 1296-1306, 2023 | 66 | 2023 |
| Antitumor immunity induced by antibody-based natural killer cell engager therapeutics armed with not-alpha IL-2 variant O Demaria, L Gauthier, M Vetizou, AB Alvarez, C Vagne, G Habif, ... Cell Reports Medicine 3 (10), 2022 | 50 | 2022 |
| The toll-like receptor agonist imiquimod is active against prions N Oumata, PH Nguyen, V Béringue, F Soubigou, Y Pang, N Desban, ... PLoS One 8 (8), e72112, 2013 | 38 | 2013 |
